Related Experiment Video
Updated: Apr 13, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Phase 3 study results for oral PCSK9 inhibition with enlicitide
Irina Müller-Kozarez1, Ulrich Laufs1
1Klinik und Poliklinik für Kardiologie, Universitätsklinikum Leipzig, Liebigstr. 20, 04103 Leipzig, Germany.
None:
Two large randomized, placebo-controlled phase 3 trials, CORALreef Lipids1 and CORALreef heFH,2 demonstrated that once-daily oral enlicitide lowered LDL cholesterol by approximately 56%-60% on top of background lipid-lowering therapy. Reductions were sustained through 24-52 weeks and accompanied by improvements in other lipid parameters. Safety outcomes were comparable to placebo, with efficacy similar to monoclonal antibody PCSK9 inhibitors.
More Related Videos
Related Concept Videos
Atherosclerosis III: Management
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Acute Coronary Syndrome III: Diagnostic Studies
Peripheral Artery Disease III: Interprofessional Care
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Pharmacogenomics: Identification of New Drug Targets

